This site is intended for healthcare professionals

Health Canada approves Reblozyl to treat transfusion-dependent anemia resulting from low/intermediate risk myelodysplastic syndromes. - BMS.

Read time: 1 mins
Last updated:26th Feb 2021
Published:24th Feb 2021
Condition: Myelodysplastic Syndromes
Type: drug
Register for free access to this exclusive healthcare learning resource

Why sign up with Medthority?

Develop your knowledge with our disease and condition focused Learning Zones

Access content from credible sources, including expert-led commentary, videos, podcasts, and webinars as well as clinical trials, treatment information and guidelines 

Personalised dashboard providing updates and recommendations for content within your areas of interest